TY - JOUR
T1 - Biologic, clinical, and sociodemographic predictors of multi-agent systemic therapy for non-Hodgkin lymphoma in people living with HIV
T2 - a population-based investigation in the state of Georgia
AU - Lipscomb, Joseph
AU - Switchenko, Jeffrey M.
AU - Flowers, Christopher R.
AU - Gillespie, Theresa W.
AU - Wortley, Pascale M.
AU - Bayakly, A. Rana
AU - Almon, Lyn
AU - Fernando, Robyn
AU - Ward, Kevin C.
N1 - Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/3/20
Y1 - 2020/3/20
N2 - We conducted a population-based study of biologic, clinical, and sociodemographic factors associated with receipt of multi-agent systemic therapy (MAST) by people living with HIV (PLWH) who were diagnosed with non-Hodgkin lymphoma (NHL). Building on recent registry-based analyses, we linked records from the Georgia Cancer Registry, Georgia HIV/AIDS Surveillance Registry, and the Georgia Hospital Discharge Database to identify 328 PLWH adults (age ≥ 18) diagnosed with NHL within 2004–2012. Through logistic regression modeling, we examined factors associated with patients receiving MAST for NHL. Robust predictors included CD4 count ≥200 cells/mm3 around the time of cancer diagnosis, an advanced stage (III or IV) diagnosis of NHL, MSM HIV transmission, and having private health insurance. The strongest single predictor of MAST was CD4 count. Because there is now guideline-integrated evidence that PLWH receiving standard-of-care cancer therapy can achieve substantially improved outcomes, it is vital they have access to regimens routinely provided to HIV-negative cancer patients.
AB - We conducted a population-based study of biologic, clinical, and sociodemographic factors associated with receipt of multi-agent systemic therapy (MAST) by people living with HIV (PLWH) who were diagnosed with non-Hodgkin lymphoma (NHL). Building on recent registry-based analyses, we linked records from the Georgia Cancer Registry, Georgia HIV/AIDS Surveillance Registry, and the Georgia Hospital Discharge Database to identify 328 PLWH adults (age ≥ 18) diagnosed with NHL within 2004–2012. Through logistic regression modeling, we examined factors associated with patients receiving MAST for NHL. Robust predictors included CD4 count ≥200 cells/mm3 around the time of cancer diagnosis, an advanced stage (III or IV) diagnosis of NHL, MSM HIV transmission, and having private health insurance. The strongest single predictor of MAST was CD4 count. Because there is now guideline-integrated evidence that PLWH receiving standard-of-care cancer therapy can achieve substantially improved outcomes, it is vital they have access to regimens routinely provided to HIV-negative cancer patients.
KW - HIV/AIDS
KW - Non-Hodgson lymphoma
KW - multi-agent systemic therapy
KW - standard-of-care therapy
UR - http://www.scopus.com/inward/record.url?scp=85076927183&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076927183&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1702176
DO - 10.1080/10428194.2019.1702176
M3 - Article
C2 - 31852329
AN - SCOPUS:85076927183
SN - 1042-8194
VL - 61
SP - 896
EP - 904
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -